David A. Provenzano , Bradley Holt , Michael Danko , Joseph Atallah , Maaz Iqbal , Binit Shah , Albert Singh , Harsh Sachdeva , Ella Ver Donck , Erik Shaw , Sherri Haas , Rajat Sekhar , Ann Pan , Daniel S. Halperin , Edward Goldberg
{"title":"腰椎射频消融术治疗慢性疼痛(RAPID)患者的真实、前瞻性结果评估","authors":"David A. Provenzano , Bradley Holt , Michael Danko , Joseph Atallah , Maaz Iqbal , Binit Shah , Albert Singh , Harsh Sachdeva , Ella Ver Donck , Erik Shaw , Sherri Haas , Rajat Sekhar , Ann Pan , Daniel S. Halperin , Edward Goldberg","doi":"10.1016/j.inpm.2025.100576","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Lumbar facet joint syndrome (LFJS) is one of most common forms of chronic low back pain. Despite several decades of real-world use and a plethora of published studies, debate still exists regarding the effectiveness of Radiofrequency Ablation (RFA) as a therapy in LFJS-diagnosed patients.</div></div><div><h3>Objective</h3><div>Here, we sought to evaluate real-world clinical outcomes in RFA-treated patients with chronic lumbar facetogenic pain participating in one of the largest studies of its kind published to date.</div></div><div><h3>Methods</h3><div>The RAPID study (Clinicaltrials.gov identifier: NCT04673032) is an international, multicenter, prospective study of patients using a commercially-available radiofrequency ablation system for the treatment of chronic pain, provided per standard of care. Patients were assessed at pre-specified study follow-up visits (1-, 3-. 6-, 12-, and 24-months post-index procedure). Key clinical endpoint measures collected and evaluated include NRS (pain score), Oswestry Disability Index (functional disability, ODI), EQ-5D-5L (quality-of-life), and Patient Global Impression of Change (PGIC).</div></div><div><h3>Results</h3><div>To date, 193 patients have been enrolled in this lumbar facetogenic pain patient cohort. Evaluation of pain relief amongst patients assessed out to 24-months demonstrated a mean NRS score of 3.4 (baseline NRS: 6.6, p < 0.0001). Consistent functional improvement out to 24-months was observed per an 8.6-point mean ODI score reduction (baseline ODI: 38.0, p < 0.0001). Following RFA treatment at 1-month and out to 24-months, 77.0% and 79.0% of patients were observed to be treatment responders (i.e., ≥50% pain relief), respectively. Enhanced levels in measures of quality-of-life (EQ-5D-5L) and self-reported health-related change (PGIC) were also consistently noted.</div></div><div><h3>Conclusions</h3><div>Clinically meaningful and durable improvements in pain relief, functional disability, quality-of-life and treatment satisfaction were observed across all RAPID study follow-up visits. The results of the RAPID study provide for the potential clinical outcomes amongst selected patients with lumbar facetogenic pain within the real-world clinical setting.</div></div>","PeriodicalId":100727,"journal":{"name":"Interventional Pain Medicine","volume":"4 2","pages":"Article 100576"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of real-world, prospective outcomes in patients treated with lumbar radiofrequency ablation for chronic pain (RAPID)\",\"authors\":\"David A. Provenzano , Bradley Holt , Michael Danko , Joseph Atallah , Maaz Iqbal , Binit Shah , Albert Singh , Harsh Sachdeva , Ella Ver Donck , Erik Shaw , Sherri Haas , Rajat Sekhar , Ann Pan , Daniel S. Halperin , Edward Goldberg\",\"doi\":\"10.1016/j.inpm.2025.100576\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Lumbar facet joint syndrome (LFJS) is one of most common forms of chronic low back pain. Despite several decades of real-world use and a plethora of published studies, debate still exists regarding the effectiveness of Radiofrequency Ablation (RFA) as a therapy in LFJS-diagnosed patients.</div></div><div><h3>Objective</h3><div>Here, we sought to evaluate real-world clinical outcomes in RFA-treated patients with chronic lumbar facetogenic pain participating in one of the largest studies of its kind published to date.</div></div><div><h3>Methods</h3><div>The RAPID study (Clinicaltrials.gov identifier: NCT04673032) is an international, multicenter, prospective study of patients using a commercially-available radiofrequency ablation system for the treatment of chronic pain, provided per standard of care. Patients were assessed at pre-specified study follow-up visits (1-, 3-. 6-, 12-, and 24-months post-index procedure). Key clinical endpoint measures collected and evaluated include NRS (pain score), Oswestry Disability Index (functional disability, ODI), EQ-5D-5L (quality-of-life), and Patient Global Impression of Change (PGIC).</div></div><div><h3>Results</h3><div>To date, 193 patients have been enrolled in this lumbar facetogenic pain patient cohort. Evaluation of pain relief amongst patients assessed out to 24-months demonstrated a mean NRS score of 3.4 (baseline NRS: 6.6, p < 0.0001). Consistent functional improvement out to 24-months was observed per an 8.6-point mean ODI score reduction (baseline ODI: 38.0, p < 0.0001). Following RFA treatment at 1-month and out to 24-months, 77.0% and 79.0% of patients were observed to be treatment responders (i.e., ≥50% pain relief), respectively. Enhanced levels in measures of quality-of-life (EQ-5D-5L) and self-reported health-related change (PGIC) were also consistently noted.</div></div><div><h3>Conclusions</h3><div>Clinically meaningful and durable improvements in pain relief, functional disability, quality-of-life and treatment satisfaction were observed across all RAPID study follow-up visits. The results of the RAPID study provide for the potential clinical outcomes amongst selected patients with lumbar facetogenic pain within the real-world clinical setting.</div></div>\",\"PeriodicalId\":100727,\"journal\":{\"name\":\"Interventional Pain Medicine\",\"volume\":\"4 2\",\"pages\":\"Article 100576\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interventional Pain Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772594425000378\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional Pain Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772594425000378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:腰椎关节突关节综合征(LFJS)是慢性腰痛最常见的形式之一。尽管有几十年的实际应用和大量发表的研究,关于射频消融(RFA)作为lfjs诊断患者治疗的有效性仍然存在争议。目的:在此,我们试图评估rfa治疗的慢性腰椎面源性疼痛患者的真实临床结果,这些患者参与了迄今为止发表的同类研究中规模最大的研究之一。RAPID研究(Clinicaltrials.gov识别码:NCT04673032)是一项国际、多中心、前瞻性研究,研究对象是使用市售射频消融系统治疗慢性疼痛的患者,提供标准护理。在预先指定的研究随访中评估患者(1-,3-)。术后6、12、24个月)。收集和评估的主要临床终点指标包括NRS(疼痛评分)、Oswestry残疾指数(功能残疾,ODI)、EQ-5D-5L(生活质量)和患者总体变化印象(PGIC)。结果迄今为止,193名患者被纳入腰椎面部疼痛患者队列。24个月的疼痛缓解评估显示,平均NRS评分为3.4(基线NRS: 6.6, p <;0.0001)。每降低8.6分的平均ODI评分(基线ODI: 38.0, p <;0.0001)。RFA治疗1个月和24个月后,77.0%和79.0%的患者分别观察到治疗反应(即疼痛缓解≥50%)。生活质量(EQ-5D-5L)和自我报告的健康相关变化(PGIC)的水平也得到了提高。结论:在所有RAPID研究随访中观察到疼痛缓解、功能残疾、生活质量和治疗满意度的临床意义和持久的改善。RAPID研究的结果提供了真实世界临床环境中腰椎面源性疼痛患者的潜在临床结果。
Assessment of real-world, prospective outcomes in patients treated with lumbar radiofrequency ablation for chronic pain (RAPID)
Background
Lumbar facet joint syndrome (LFJS) is one of most common forms of chronic low back pain. Despite several decades of real-world use and a plethora of published studies, debate still exists regarding the effectiveness of Radiofrequency Ablation (RFA) as a therapy in LFJS-diagnosed patients.
Objective
Here, we sought to evaluate real-world clinical outcomes in RFA-treated patients with chronic lumbar facetogenic pain participating in one of the largest studies of its kind published to date.
Methods
The RAPID study (Clinicaltrials.gov identifier: NCT04673032) is an international, multicenter, prospective study of patients using a commercially-available radiofrequency ablation system for the treatment of chronic pain, provided per standard of care. Patients were assessed at pre-specified study follow-up visits (1-, 3-. 6-, 12-, and 24-months post-index procedure). Key clinical endpoint measures collected and evaluated include NRS (pain score), Oswestry Disability Index (functional disability, ODI), EQ-5D-5L (quality-of-life), and Patient Global Impression of Change (PGIC).
Results
To date, 193 patients have been enrolled in this lumbar facetogenic pain patient cohort. Evaluation of pain relief amongst patients assessed out to 24-months demonstrated a mean NRS score of 3.4 (baseline NRS: 6.6, p < 0.0001). Consistent functional improvement out to 24-months was observed per an 8.6-point mean ODI score reduction (baseline ODI: 38.0, p < 0.0001). Following RFA treatment at 1-month and out to 24-months, 77.0% and 79.0% of patients were observed to be treatment responders (i.e., ≥50% pain relief), respectively. Enhanced levels in measures of quality-of-life (EQ-5D-5L) and self-reported health-related change (PGIC) were also consistently noted.
Conclusions
Clinically meaningful and durable improvements in pain relief, functional disability, quality-of-life and treatment satisfaction were observed across all RAPID study follow-up visits. The results of the RAPID study provide for the potential clinical outcomes amongst selected patients with lumbar facetogenic pain within the real-world clinical setting.